Dan Whitfield for Arkansas US Inactive
DANWHITCONGRESS
⚠ Creative removed by Meta
This ad's image was taken down for violating Meta's ad standards; the copy below is preserved from the Ad Library.
This ad's image was taken down for violating Meta's ad standards; the copy below is preserved from the Ad Library.
Ad copy
Pharmaceutical companies should sell the COVID-19, Corona Virus, vaccine AT COST. This is not a time to profiteer or capitalize on an epidemic. Arkansans should receive paid sick leave for the time they are away from work due to this state of emergency event. www.ReplaceTomCotton.com
↗ View in Meta Ad Library (the live creative — image/video/layout)
Performance proxies
| Overall score | 18.9/100 |
| Spend / Reach / Long. / Eff. | 0.0 · 24.3 · 0.0 · 51.2 |
| Spend range | <USD 99 |
| Impressions | 100 – 999 |
| CPM (≈ $/1k impr) | USD 90.08 |
| Est. audience size | — |
| Days live | 1 (2020-03-13 → 2020-03-13) |
| Created | 2020-03-12 |
| Creative variants | 1 body · 0 headline |
| Platforms | |
| Languages | en |
| Candidate | AR — Dan Whitfield |
| Surfaced by | “senate:Dan Whitfield” |
🧠 AI analysis
| Issue | healthcare |
| Framing | issue advocacy |
| Message type | persuasion |
| Emotional appeal | anger |
| Production tier | diy amateur |
| Who pictured | candidate |
| Symbols | none |
| Call to action | none |
| Standout element | Facebook content removal notice displayed as the ad itself, exposing platform censorship |
| Tactic | The ad leverages a COVID-19 economic fairness argument against pharmaceutical profiteering and lack of paid sick leave, implicitly contrasting Whitfield against incumbent Tom Cotton, though its impact is undermined by the platform's disclaimer removal notice. |
Where it ran (delivery by region)
| Arkansas | 100.0% |
Who saw it (delivery)
| 55-64 · female | 16.4% |
| 45-54 · unknown | 0.2% |
| 25-34 · unknown | 0.3% |
| 65+ · unknown | 0.3% |
| 18-24 · female | 0.8% |
| 35-44 · unknown | 0.3% |
| 45-54 · female | 8.9% |
| 18-24 · male | 1.0% |
| 55-64 · male | 11.2% |
| 35-44 · male | 7.1% |
| 25-34 · female | 3.6% |
| 35-44 · female | 10.0% |
| 45-54 · male | 8.4% |
| 25-34 · male | 3.9% |
| 65+ · female | 18.6% |
| 65+ · male | 8.9% |
| 55-64 · unknown | 0.2% |
